Access to New Medications for Hepatitis C for Medicaid Members: A Retrospective Cohort Study

BACKGROUND: Sofosbuvir (SOF)- or simeprevir (SIM)-containing regimens are highly effective for treating chronic hepatitis C virus (HCV) infection. These regimens, however, are expensive. Most payers have implemented prior authorization (PA) requirements to ensure that patients who can benefit most h...

Descripción completa

Detalles Bibliográficos
Autores principales: Clements, Karen M., Clark, Robin E., Lavitas, Pavel, Kunte, Parag, Graham, Camilla S., O’Connell, Elizabeth, Lenz, Kimberly, Jeffrey, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397595/
https://www.ncbi.nlm.nih.gov/pubmed/27231798
http://dx.doi.org/10.18553/jmcp.2016.22.6.714

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397595/
https://www.ncbi.nlm.nih.gov/pubmed/27231798
http://dx.doi.org/10.18553/jmcp.2016.22.6.714

Ejemplares similares